Revenue for the quarter was ₹5320 Cr ($715 million). Growth of 8% YoY and declined 8% sequentially. YoY growth is due to good performance across all segments. Sequential decline due to high base in Q2 which had a higher contribution from COVID related products. Gross Profit margin for the quarter was 53.8%, increase of 40 …
They have had a very strong quarter – especially in CRAMS where the pipeline continues to be very strong. They are seeing good interest and strong growth in the Vitamin D analogues. The cholesterol business is stable and the disinfectant business is seeing increased interest from customers. They have seen a rapid rise in transportation …
Revenue growth was at 6%. EBITDA margins were at 22.7% which tracks with their full year guidance despite increased RM and freight costs. The cost increases were offset by increased share of the complex and chronic launches, continuous rigor on cost control and operating efficiencies. One India reported 13% growth YoY. The core prescription business …
They handle manufacturing and last mile distribution for their products which allows them to eliminate intermediaries. They have managed to replace importers in the smaller geographies and will be replacing distributors in larger geographies like USA, Mexico, Brazil, Europe, South Africa and CIS countries. They have identified a niche in the Mexico market where they …
Revenues for the quarter were at ₹3655 Cr (1% growth YoY). Excluding COVID related products, growth was 5% YoY. EBITDA stood at ₹750 Cr and EBITDA margins were at 20.6% compared to 21.1% in the same quarter last year. PAT for the quarter was at ₹500 Cr. Branded Generics portfolio in India delivered a strong …
Revenues for the quarter stood at ₹6002 Cr (1% decline YoY). EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY). Revenue from formulations was ₹4992 Cr (12% decline YoY). Formulations contributed about 83% of total revenues. Revenue from …
Revenues for the quarter stood at ₹1272 Cr (3% decline YoY). EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter. PAT stood at 176 Cr (40% decline YoY). They believe the price erosion in the US business has normalized and they can grow with new launches …
The company has announced a buyback of ₹352 Cr including taxes. Including dividend, total payout to the shareholder for the financial year is at ₹434 Cr Emerging Markets business (Branded Generics) – Spread across Asia and Africa and contributes 41% of revenues. Exports to these markets were ₹361 Cr (26% growth YoY). Sales to Asia …
The financial performance is not exactly comparable especially in terms of realizations and margins because of elevated API prices driven by COVID related issues last year. The company posted robust growth in revenues and margins on a sequential basis despite high freight costs, elevated coal prices and high RM prices. Standalone Q3 revenue stood at …
Revenues for the quarter stood at ₹515 Cr (11% growth YoY). EBITDA for the quarter was ₹93 Cr (2% growth YoY). EBITDA margins were 18.1% for the quarter. PAT stood at ₹45 Cr (12% growth YoY). Revenue from the Pharmaceuticals segment was ₹268 Cr which is flat YoY. Operating profit from the Pharmaceuticals segment was …